Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700324 | 0.94 | RAB9A (0.46) | TP53RAB9AHDAC4HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL11871911 | 0.94 | RAB9A (0.46) | TP53RAB9AHDAC4HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL11870858 | 0.94 | RAB9A (0.46) | TP53RAB9AHDAC4HDAC2HDAC8 | |
| SCHEMBL11879078 | 0.92 | RAB9A (0.44) | TP53RAB9AHDAC4HDAC2HDAC8 | |
| SCHEMBL9102041 | 0.92 | RAB9A (0.44) | TP53RAB9AHDAC4HDAC2HDAC8 | |
| SCHEMBL28330036 | 0.90 | — | — | |
| Isoleucine SCHEMBL5564710 | 0.80 | KMT2A (0.38) | TP53RAB9AGRIA1GRIA3GRIA4 | |
| Isoleucine SCHEMBL5564713 | 0.80 | KMT2A (0.38) | TP53RAB9AGRIA1GRIA3GRIA4 | |
| Hydrochloric Acid SCHEMBL11871905 | 0.79 | HDAC4 (0.38) | TP53RAB9AHDAC4HDAC2HDAC8 | |
| SCHEMBL11874913 | 0.77 | HDAC4 (0.39) | RAB9AHDAC4HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877738-B2 | Antipathogenic peptides | SPIDERBIOTECH S.R.L. (IT) | 2014-11-04 | — | — | US | claimed |
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | claimed |
| EP-2462155-A1 | NOVEL ANTIPATHOGENIC PEPTIDES | Spiderbiotech S.r.l. (IT) | 2012-06-13 | — | — | EP | claimed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | claimed |
| US-20120121623-A1 | NOVEL ANTIPATHOGENIC PEPTIDES | SPIDERBIOTCH S.r.L. (IT) | 2012-05-17 | — | — | US | claimed |
| WO-2011015628-A1 | NOVEL ANTIPATHOGENIC PEPTIDES | SPIDERBIOTECH S.R.L. (IT) | 2011-02-10 | — | — | WO | claimed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | claimed |
| US-6649814-B2 | Nucleotide sequences coding enzymatic polypeptide for use in the generation of disease, pest and insect resistant plants | SYNGENTA PARTICIPATIONS AG (CH) | 2003-11-18 | — | — | US | claimed |
| US-20030041346-A1 | Cytochrome P450 monooxygenases | HALKIER BARBARA A (DK) | 2003-02-27 | — | — | US | claimed |
| US-6300544-B1 | ISOLATED NUCLEIC ACIDS; CATALYZES THE CONVERSION OF AN ALDOXIME TO THE CORRESPONDING NITRILE AND THEN TO THE CYANOHYDRIN FOR BIOSYNTHESIS OF CYANOGLYCOSIDES; PEST RESISTANT TRANSGENIC PLANTS OR PLANTS WITH NUTRITIVE VALUE | SYNGENTA PARTICIPATIONS AG (CH) | 2001-10-09 | — | — | US | claimed |
| EP-0970191-A2 | CYTOCHROME P450 MONOOXYGENASES | Novartis AG (CH) | 2000-01-12 | — | — | EP | claimed |
| WO-1998040470-A2 | CYTOCHROME P450 MONOOXYGENASES | NOVARTIS AG (CH) | 1998-09-17 | — | — | WO | claimed |
| CN-108671060-A | A kind of Traditional Chinese medicine bacteriostatic disinfectant lotion and preparation method thereof | 王世鑫 | 2018-10-19 | — | — | CN | disclosed |
| CN-104958460-A | External lotion for treating scabies and preparation method | WANG XINGTONG | 2015-10-07 | — | — | CN | disclosed |
| EP-2462155-B1 | NOVEL ANTIPATHOGENIC PEPTIDES | SPIDERBIOTECH SRL (IT) | 2015-05-27 | — | — | EP | disclosed |
| US-8877738-B2 | Antipathogenic peptides | SPIDERBIOTECH S.R.L. (IT) | 2014-11-04 | — | — | US | disclosed |
| WO-1995016041-A1 | CYTOCHROME P-450 MONOOXYGENASES | CIBA-GEIGY AG (CH) | 1995-06-15 | — | — | WO | disclosed |
| CN-1082533-A | The preparation method who is used for the 1-cyclopentyl alkanamine of synthetic sweetener | COCA COLA CO (US) | 1994-02-23 | — | — | CN | disclosed |
| WO-1994002441-A1 | A PROCESS FOR MAKING 1-CYCLOPENTYLALKYL AMINES USEFUL FOR THE SYNTHESIS OF SWEETENERS | THE COCA-COLA COMPANY (US) | 1994-02-03 | — | — | WO | disclosed |
| US-5225591-A | One-step reduction of an azanorbornene | THE COCA-COLA COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | TP53 4797/4885RAB9A 2128/4885HDAC4 1713/4885 |
| US-20120121623-A1 | NOVEL ANTIPATHOGENIC PEPTIDES | MAVS, VIP, ZC3HAV1 | TP53 838/4885RAB9A 3088/4885HDAC4 3927/4885 |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | TP53 4797/4885RAB9A 2128/4885HDAC4 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.